| Variable | N (%) |
| Age (years) |
|
| 40 - 50 | 12 (10.71) |
| 51 - 60 | 29 (25.89) |
| 61 - 70 | 42 (37.50) |
| 71 - 80 | 25 (22.32) |
| >80 | 4 (3.57) |
| Pathology |
|
| Benign prostatic hypertrophy | 73 (65.18) |
| Prostate cancer | 39 (34.82) |
| Symptoms |
|
| Obstructive symptoms only | 56 (50) |
| Irritative symptoms only | 5 (4.46) |
| Obstructive and irritative symptoms | 20 (17.86) |
| Macroscopic hematuria | 8 (7.14) |
| Urinary tract infections | 7 (6.25) |
| Acute urinary retention | 16 (14.29) |
| Digital rectal examination |
|
| Unremarkable | 74 (66.07) |
| Positive | 38 (33.93) |
| QoL score |
|
| 3 | 14 (12.50) |
| 4 | 30 (26.79) |
| 5 | 40 (35.71) |
| 6 | 28 (25.00) |
| IPSS score |
|
| 0 - 7 | 0 (00) |
| 8 - 19 | 29 (25.89) |
| 20 - 35 | 83 (74.11) |
| Prostate diameter (mm) |
|
| 30 - 60 | 37 (33.04) |
| 61 - 90 | 52 (46.43) |
| 91 - 120 | 20 917.86) |
| >120 | 14 (12.50) |
| Serum PSA level (ng/ml) |
|
| 0 - 20 | 73 (65.18) |
| 21 - 100 | 25 (22.32) |
| >100 | 14 (12.50) |
| Qmax (ml/s) |
|
| <10 | 49 (43.75) |
| 10 - 15 | 63 (56.25) |
| >15 | 0 |
| Indication for surgery |
|
| Treatment failure | 61 (54.46) |
| Prostatic adenocarcinoma | 31 (27.68%) |
| Choice | 13 (11.61%) |
| Acute urinary retention | 4 (3.57%) |
| Recurrent urinary tract infections | 3 (2.68%) |